Omeros Corporation (OMER) Earnings Call Transcripts

Omeros Corporation's Latest Earnings Call - Q4 FY2025

In the fourth quarter of 2025, Omeros Corporation (OMER:US) reported a significant turnaround with a net income of $86.5 million or $1.22 per share, primarily driven by a $237.6 million gain from the sale of zaltenibart to Novo Nordisk. This quarter's results represent a stark contrast to the previous quarter's net loss of $30.9 million. Management highlighted the successful launch of YARTEMLEA, the first approved treatment for TA-TMA, and anticipates that the program will be financially self-sustaining in 2026, with a target for positive cash flow by 2027.

Reported metrics

Guidance from management

Management expects YARTEMLEA to be financially self-sustaining in 2026 and anticipates achieving positive cash flow by 2027. They did not provide specific revenue guidance for the first quarter of 2026 due to the early stage of the product launch.

What management said

Brandon, thanks. With respect to the first question, we're quite pleased with the P&T committee approvals that we've received so far that YARTEMLEA has received. It was really ahead of schedule, which I think indicates the strong interest and frankly, the recognized need for the drug. I expect -- I think we expect that we will continue to see additional P&T approvals over the next several months. And our objective,...

Yes, I completely agree with everything you said, Greg. And I will underscore how pleased we are with the speed with which these P&T decisions are being taken, which isn't always the case in a launch. Here, they're seeing the value and the urgency to treat patients with YARTEMLEA's value proposition. And I will add that in places where we don't have P&T approval yet, if it's still underway, it's not standing in the...

What analysts pressed on

Analysts expressed concerns regarding the pace of formulary additions across transplant centers and the real-world vial usage of YARTEMLEA. They are particularly interested in understanding how quickly the company can respond to urgent patient needs and the potential roadblocks in the early stages of the launch.

Main topics on the call

• Zaltenibart Transaction — Omeros completed a significant asset sale to Novo Nordisk for $240 million upfront, with potential total deal value of up to $2.1 billion. Management stated, "The transaction resulted in an upfront cash payment to Omeros...
• YARTEMLEA Launch Progress — YARTEMLEA has been launched successfully, with early sales occurring shortly after FDA approval. Management noted, "We began preparations for the U.S. commercial launch of YARTEMLEA well before receiving approval, allowi...
• P&T Committee Approvals — YARTEMLEA has received P&T committee approvals at 50% of the top 10 U.S. transplant centers, which is ahead of schedule. Management expressed confidence, stating, "We're quite pleased with the P&T committee approvals tha...
• Financial Health Improvement — Omeros improved its balance sheet by repaying a $67.1 million term loan and a $17.1 million convertible note, leaving only $70.8 million in convertible notes due in 2029. Management highlighted, "As a result, all indebte...

Read the full Omeros Corporation transcript (Q4 FY2025) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 35 Omeros Corporation earnings call transcripts on record, spanning March 2, 2020 to August 12, 2026. Based on this history, Omeros Corporation reports quarterly. The most recent call on file is dated August 12, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

OMER

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

35

First call

March 2, 2020

Most recent

August 12, 2026

Reporting cadence

quarterly